Phase II Study of the Histone Deacetylase Inhibitor MGCD0103 in Patients with Previously Treated Chronic Lymphocytic Leukemia

MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/day, three times per week. Dose escalation to 110 mg or the addition of ritu...

詳細記述

保存先:
書誌詳細
主要な著者: Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2779118/
https://ncbi.nlm.nih.gov/pubmed/19747365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07881.x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料